IONQ Inc vs Tilray Brands Inc — how do they compare? IONQ Inc trades at $39.9 (market cap $15.98B), while Tilray Brands Inc trades at $3.54 (market cap $530.54M). The key difference: IONQ Inc is far larger — about 30.1× Tilray Brands Inc's market cap, and IONQ Inc is trading nearer its 52-week high, Tilray Brands Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IONQ Inc for 33 Days and Tilray Brands Inc for 31 Days on average.
| IONQ | TLRY | |
|---|---|---|
Market Cap | $15.98B | $530.54M |
Volume | 22,848,240 | 9,099,075 |
Sector | Technology | Health |
52-Week High | $82.09 | $21.00 |
52-Week Low | $26.59 | $3.57 |
Typical Hold Time | 33 Days | 31 Days |
Enterprise Value | $13.92B | $684.46M |
Signals from Pluang's Aura AI — not financial advice
IONQ trades at $39.89, down 3.51% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported revenue of $130.02M in 2025 but a net loss of $510.38M, with a high P/S ratio of 54.74. Recent news highlights Bank of America's Buy rating and $60 price target, citing IonQ's semiconductor-based quantum computing approach as a key growth driver.
The stock presents high-risk, high-reward potential with strong analyst optimism but faces significant execution risks amid widening losses. Upside depends on scaling quantum technology profitably, while downside risks include cash burn and competitive threats. The consensus price target of $62.75 suggests substantial upside if growth targets are met.
Tilray Brands (TLRY) trades at $3.50, down 5.79% on the day and near its 52-week low. The stock shows bearish technical signals with negative moving averages and recent earnings misses across four consecutive quarters. Despite revenue growth to $821 million in 2025, the company reported a substantial net loss of $2.19 billion, driven by impairment charges and high operating costs. Analyst sentiment remains cautious with 65% hold ratings, though the consensus price target of $65.01 suggests significant potential upside from current levels.
The outlook remains challenging with persistent profitability issues and negative cash flow from operations. Investment opportunity exists if Tilray can achieve projected 2026 revenue growth to $915 million and reduce losses. Key risks include ongoing operational inefficiencies, competitive pressures in the cannabis market, and regulatory uncertainty. The stock's current valuation at 0.44 P/S and 0.33 P/B may attract value investors betting on a turnaround.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
IonQ is a leader in quantum computing, developing world-class quantum systems. Its technology aims to solve complex problems across finance, healthcare, and materials science that are beyond classical computers.
Read more on IONQ →Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →